TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI) has announced that in a study of chronic sinusitis (CS) patients refractory to sinus surgery, treated with various strengths of extemporaneously prepared pump-spray formulations of intranasal amphotericin B, a formulation containing a mid-range concentration of amphotericin B was associated with a significant, 74% reduction in repeat sinus surgery (P=0.01) when given over a one-year period of continued usage. The retrospective study from a surgical practice was updated and presented in a poster session at the recent 2006 American Academy of Otolanyngology-Head and Neck Surgery Foundation meeting in Toronto.
